Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda region

Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda region

The article presents the experience of using biopharmaceutical products for the treatment of children with juvenile idiopathic arthritis in the cardio-rheumatological department of the PSE “Children’s Hospital of Karaganda” for the period from January 1, 2013, to December 31, 2017. The study include...

Full description

Bibliographic Details
Main Authors:	Kenzhetaeva Tattigul, Serikova Gulmira, Alimshaikhina Kulzhazira, Issayeva Aiman, Sabiyeva Makpal, Sarmankulova Gulmira
Format:	Article
Language:	English
Published:	EDP Sciences 2024-01-01
Series:	BIO Web of Conferences
Subjects:	juvenile idiopathic arthritis genetically engineered biological drugs anti-tnf drugs anti-interleukin-6 drugs
Online Access:	https://www.bio-conferences.org/articles/bioconf/pdf/2024/03/bioconf_aquaculture2024_03028.pdf

Similar Items

Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA)
by: A. Nassar-Sheikh Rashid, et al.
Published: (2021-04-01)

10 - year experience in the application of biological therapy to patients with juvenile idiopathic arthritis
by: Zaure Mukusheva, et al.
Published: (2017-09-01)

Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry
by: Giulia Armaroli, et al.
Published: (2020-10-01)

Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches
by: Lina N. Zaripova, et al.
Published: (2021-08-01)

Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis
by: Mia Lindegaard Pedersen, et al.
Published: (2023-09-01)

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany
by: Arnd Heiligenhaus, et al.
Published: (2020-04-01)

Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country
by: Juliana Barbosa Brunelli, et al.

Bone mineral density in children with juvenile idiopathic arthritis after one year of treatment with etanercept
by: Sušić Gordana, et al.
Published: (2018-01-01)

Features of the course and treatment of JIA-associated uveitis
by: M.V. Panchenko, et al.
Published: (2019-04-01)

A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis
by: Daniel J. Lovell, et al.
Published: (2018-06-01)

The effect of etanercept therapy on adrenal steroid metabolism in juvenile idiopathic arthritis: a steroid metabolomics approach
by: Yonatan Butbul Aviel, et al.
Published: (2023-04-01)

Bilateral Panuveitis at Etanercept Initiation for Juvenile Idiopathic Arthritis
by: Kaouther Ben Abdelghani, et al.
Published: (2014-03-01)

In a large Juvenile Idiopathic Arthritis (JIA) cohort, concomitant celiac disease is associated with family history of autoimmunity and a more severe JIA course: a retrospective study
by: Roberta Naddei, et al.
Published: (2022-04-01)

Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report
by: Koichi Sugihara, et al.
Published: (2021-09-01)

Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors
by: Job Gieling, et al.
Published: (2022-12-01)

Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study
by: Luiza R. Grazziotin, et al.
Published: (2022-04-01)

Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study
by: Ryoki Hara, et al.
Published: (2019-04-01)

THE PHENOMENON OF NEUTROPENIA DURING TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
by: M. I. Kaleda, et al.
Published: (2018-01-01)

Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
by: Tiina Levälampi, et al.
Published: (2023-03-01)

Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients
by: M. Romano, et al.
Published: (2014-03-01)

Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre
by: Maxime Goirand, et al.
Published: (2018-04-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
by: R. Talotta, et al.
Published: (2016-09-01)

Juvenile Idiopathic Arthritis, Uveitis and Multiple Sclerosis: Description of Two Patients and Literature Review
by: Cecilia Beatrice Chighizola, et al.
Published: (2022-08-01)

Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the “comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS” (STARS) trial
by: Marco Burrone, et al.
Published: (2022-09-01)

Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia
by: Ekaterina I. Alexeeva, et al.
Published: (2017-06-01)

Fatal myocarditis in a child with systemic onset juvenile idiopathic arthritis during treatment with an interleukin 1 receptor antagonist
by: Zeft Andrew S, et al.
Published: (2012-04-01)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
by: Maike H. M. Wientjes, et al.
Published: (2021-06-01)

O papel dos inibidores do fator de necrose tumoral no tratamento da artrite idiopática juvenil The role of tumor necrosis factor inhibitors in the treatment of juvenile idiopathic arthritis
by: Patrícia Martin, et al.
Published: (2006-04-01)

Anti-cyclic citrullinated peptide antibodies in children with Juvenile Idiopathic Arthritis
by: Mohamed Hamooda, et al.
Published: (2016-09-01)

Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis
by: Maarit Tarkiainen, et al.
Published: (2022-11-01)

Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients
by: Laura Magill, et al.
Published: (2018-12-01)

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
by: Laure Gossec, et al.
Published: (2023-06-01)

Infection-Related Death among Persons with Refractory Juvenile Idiopathic Arthritis
by: Mario Abinun, et al.
Published: (2016-10-01)

Substance use and sexual function in juvenile idiopathic arthritis
by: Marlon van Weelden, et al.

Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study
by: Simone Parisi, et al.
Published: (2022-01-01)

Risankizumab as an effective therapeutic option in severe psoriasis unsuccessfully treated with therapies involving anti- TNF-α and anti-IL-17
by: Michał Adamczyk, et al.
Published: (2020-10-01)

TMJ pathomorphology in patients with JIA-radiographic parameters for early diagnosis-
by: Daniela Klenke, et al.
Published: (2018-09-01)

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
by: Jurgen Sota, et al.
Published: (2019-01-01)

Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
by: Claire E.H. Barber, et al.
Published: (2019-08-01)

Persistence on anti-TNF therapy - data from Serbian National Spondyloarthritis Registry
by: Cvetković Jovana, et al.
Published: (2023-01-01)